Efficacy demonstrated in 2
pivotal Phase 3 trials,
PRIME and PRIME21,2
Randomized PRIME (N=151)
DUPIXENT
300 mg Q2W after 600 mg loading dose for 24 weeks (n=75) Matched placebo for 24 weeks (n=76) PRIME2 (N=160)
DUPIXENT
300 mg Q2W after 600 mg loading dose for 24 weeks (n=78) Matched placebo for 24 weeks (n=82) |
Study population Patients (≥18 years) with:
≈60% of trial participants were on a stable regimen of background TCS/TCI therapy.
|
Primary endpoints PRIME (N=151)
Week 24
PRIME2 (N=160)
Week 12
|
Key secondary endpoints
Week 24:
|
IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids; WI-NRS, Worst Itch numerical rating scale.
Real DUPIXENT Patients
Learn about real PN patients and their journey to DUPIXENT.